Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Buzz on the Bullboards: Recognizing the best of the best

Investors don’t prosper on potential. Investors prosper on returns. These days, plenty of companies are able to reward return-starved investors with a strong stock performance. However, many still look to short-term trading or chasing momentum for a qu...
Jonathon Brown | February 22, 2024 |

Aben Resources Expands Footprint in the Golden Triangle

Aben Resources (TSX.V: ABN | OTCQB: ABNAF ) In this exclusive interview, James Pettit of Aben Resources sits down with Maurice Jackson of Proven and Probable to discuss the latest drill results for the North Boundary Zone on the f...
Maurice Jackson | September 27, 2019 |

INmune Bio Targeting Cancer, Alzheimer's and NASH Simultaneously

We are initiating coverage on INmune Bio Inc. (INMB:NASDAQ) . According to the company, INmune is "Reprogramming the Innate Immune System for the Treatment of Diseases." On the surface, this sounds like a fairly standard biotech tagline, but there's a more here than me...
Streetwise Reports | December 5, 2019 |

Poised for a Huge Bounce: Canada’s Most Technologically Advanced LP

While some cannabis companies struggle with the emerging Canadian market, others are showing they know exactly how to make it work. The cannabis companies that are making it in are playing it smart, recognizing where the market is at and where it’s going, an...
Cindy Broad | February 12, 2020 |

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study

Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency. After U.S. markets...
Streetwise Reports | January 13, 2020 |

Crescat Gets Activist on Gold #1

We have been hard at work negotiating deals in select gold and silver exploration companies. In our hedge funds, we have been investing in private placements in public companies, often at significant discounts with warrants. We are building activist positions in some the...
Featured Submission | June 26, 2020 |

PhaseBio Shares Are on a Tear After Reporting Phase 2a Trial Results

The clinical-stage biopharmaceutical stock surged more than 30% Wednesday following a report that PB2452 caused immediate and sustained reversal of ticagrelor in older and elderly subjects. In a press release issued September 24, PhaseBio Pharmaceuticals Inc. (PHAS...
Streetwise Reports | September 26, 2019 |

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'

The compelling aspects of this life sciences story are presented in a Dawson James report. In a Jan. 28 research note, analyst Jason Kolbert reported that Dawson James Securities increased its target price on Mesoblast Ltd. (MESO:NASDAQ; MSB:ASX) to $15 pe...
Streetwise Reports | February 3, 2020 |

Amgen Shares React Favorably to Enbrel Patent Case Victory

Amgen shares are trading 5–6% higher today on news that the company has won its Enbrel (etanercept) patent court case. On Friday, August 9, 2019, Amgen Inc. (AMGN:NASDAQ) announced that it had won its Enbrel patent case. The company advised that the U.S. District C...
Streetwise Reports | August 14, 2019 |

Ellomay Capital Shares Get a Spark from 265 MW Italian Photovoltaic Development Projects

Shares of Israel-based renewable energy firm Ellomay Capital got a jolt today after the firm released details of the development plans for photovoltaic projects in Italy with aggregate capacity of 265 megawatts. Renewable energy and power generator and developer of re...
Streetwise Reports | December 31, 2019 |
1 2 3 4 5 6 7 8